The Extended Brief
DeepMind spinout Isomorphic Labs lands $5B Series C to take AI-designed medicines into the clinic

Brief by The AI News AI newsroom · Nov 17, 2026, 11:11 AM EST edition
Original reporting by Tech Funding News — Abhinaya Prabhu · published Nov 17, 2026, 10:23 AM EST
A $5 billion raise gives AI-designed drug candidates a funded path into human clinical trials, the real test of whether AlphaFold-style prediction yields actual medicines.
Key points
- Isomorphic Labs raised $5 billion in an oversubscribed Series C co-led by Greenoaks and Sequoia Capital. source ↗
- Bloomberg reported a valuation near $50 billion; Isomorphic did not disclose one. source ↗
- The funding advances its IsoDDE design engine and moves first drug candidates toward clinical trials. source ↗
- The round follows a $2.1 billion Series B in May 2026 led by Thrive Capital. source ↗
- TFN calculates total external funding now reaches about $7.7 billion, including a $600 million March 2025 round. source ↗
The data
TFN calculates total external funding of about $7.7 billion.
$50B
Valuation reported by Bloomberg
Isomorphic did not disclose a valuation; Bloomberg reported roughly $50 billion on November 4.
Numbers from the original article, machine-verified against its text
Practical applications
- Pharma and biotech teams scouting AI discovery partners should treat Isomorphic's move toward clinical trials as a trigger to benchmark IsoDDE-style platforms against their own pipelines.
- Investors and strategy leads in AI drug discovery should revisit sector valuation benchmarks, since a reported ~$50 billion mark reprices comparable companies.
- Computational chemistry teams can track which therapeutic areas Isomorphic enters first to gauge where multi-modality AI molecule design is maturing fastest.
Context
Isomorphic Labs is a London-based AI drug-discovery company founded by Demis Hassabis, who is also CEO of Google DeepMind, and its ambition builds on DeepMind's AlphaFold protein-structure work. Its IsoDDE platform combines foundational simulation models with AI agents to predict biological interactions and search chemical space for drug-like molecules across multiple therapeutic areas and drug modalities. The broader bet of AI drug discovery is that such prediction can cut the cost and time of finding candidates before human trials.
What to watch
- First clinical-trial starts for Isomorphic-designed candidates would confirm whether AI-designed molecules translate into human studies.
- Official confirmation or filing of the roughly $50 billion valuation Bloomberg reported would settle the number Isomorphic declined to disclose.
Related briefs
- Large language models detect methodological errors that human peer review misses in clinical trials
- A 10-year-old CNN outperforms frontier LLMs for skin cancer diagnosis
- Subversion of clinical judgment by conversational artificial intelligence
- Claude discovers a novel enzyme system with CRISPR-like repeats
Editorial score 3.7 / 5 · significance 4.0 · novelty 4.0 · edge 3.5 · perspective 3.0
Topics: AI in health & biotech · Pricing & economics
Evidence basis: Reviewed from the article's full text
This brief was written by The AI News AI newsroom in its own words after two independent AI reviewers voted the story worth reading. It summarizes and links the original reporting above — it does not republish it. See the methodology or the corrections ledger.